ARCHIVES

Q & A: NCI’s Doroshow Says Phase I Program Will Stress Correlative Studies for Small Biotech Firms

This article is from The Cancer Letter archive.

Vol. 38 No. 14 | April 6, 2012

Download PDF Visit The Full Archive

Related Articles

NCI Pushing Ahead With Antismoking Campaign Involving Entire States, Physicians, Even Lawyers

March 27, 1987

Stand Up To Cancer Selects Five Groups For “Dream Team” Grants Totaling $73.6M.

May 29, 2009

NCI Advisors Criticize a Biomarker Study Touted as High Priority for NCI and FDA.

July 13, 2007

Sprycell Approved for CML

November 5, 2010

Cancer Congress Program Developed

June 27, 1980

Specific Pathology Pattern Can Predict Recurrence

August 30, 2013